Bioheng is a China-based clinical-stage biotechnology company dedicated on developing novel cellular immunotherapy for cancer.
Employees: 51-200
Founded date: 2017
Investors 1
| Date | Name | Website |
| - | Octagon Ca... | octagoninv... |
Mentions in press and media 2
| Date | Title | Description |
| 05.03.2025 | Bioheng Therapeutics Announces FDA Clearance of IND Application for CD7 UCAR T Cell Therapy in T-ALL/LBL | BOSTON, March 5, 2025 /PRNewswire/ -- Bioheng Therapeutics US LLC ("Bioheng"), a clinical-stage biotech company dedicated to developing innovative universal CAR-T cell therapies, today announced that the U.S. Food and Drug Adminis... |
| 05.04.2021 | Bioheng Biotech Raises $80M in Series B Financing | Bioheng Biotech Co., Ltd., a Nanjing, China-based clinical-stage biotechnology company dedicated on developing novel cellular immunotherapy for cancer, raised $80m in Series B financing. The round was co-led by GL Ventures, the venture capi... |